Jenburkt [JENBURPH] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Jenburkt
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Jenburkt wins in 14 metrics, Aarti Drugs wins in 6 metrics, with 0 ties. Jenburkt appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Jenburkt | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.10 | 23.59 | Jenburkt |
| Price-to-Book Ratio | 3.00 | 3.25 | Jenburkt |
| Debt-to-Equity Ratio | 2.27 | 44.92 | Jenburkt |
| PEG Ratio | 33.54 | 0.37 | Aarti Drugs |
| EV/EBITDA | 12.64 | 17.02 | Jenburkt |
| Profit Margin (TTM) | 20.97% | 7.80% | Jenburkt |
| Operating Margin (TTM) | 23.18% | 10.11% | Jenburkt |
| EBITDA Margin (TTM) | 23.18% | 10.11% | Jenburkt |
| Return on Equity | 18.66% | 12.28% | Jenburkt |
| Return on Assets (TTM) | 16.34% | 6.53% | Jenburkt |
| Free Cash Flow (TTM) | $81.92M | $674.20M | Aarti Drugs |
| Dividend Yield | 2.48% | 0.22% | Jenburkt |
| 1-Year Return | 29.00% | -2.04% | Jenburkt |
| Price-to-Sales Ratio (TTM) | 3.34 | 1.83 | Aarti Drugs |
| Enterprise Value | $4.97B | $50.34B | Aarti Drugs |
| EV/Revenue Ratio | 3.21 | 2.08 | Aarti Drugs |
| Gross Profit Margin (TTM) | 80.75% | 36.77% | Jenburkt |
| Revenue per Share (TTM) | $351 | $265 | Jenburkt |
| Earnings per Share (Diluted) | $72.61 | $20.63 | Jenburkt |
| Beta (Stock Volatility) | 0.37 | 0.21 | Aarti Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Jenburkt vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Jenburkt | -4.46% | -8.15% | -11.98% | 14.06% | 13.63% | -4.13% |
| Aarti Drugs | 3.53% | -3.86% | 1.23% | 5.23% | 18.26% | 6.84% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Jenburkt | 29.00% | 97.77% | 177.18% | 144.16% | 1,393.36% | 2,406.54% |
| Aarti Drugs | -2.04% | 8.97% | -37.88% | 208.08% | 2,669.78% | 2,338.13% |
Performance & Financial Health Analysis: Jenburkt vs Aarti Drugs
| Metric | JENBURPH | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹5.16B | ₹44.42B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,161 | 159,509 |
| 90 Day Avg. Volume | 1,086 | 613,674 |
| Last Close | ₹1,117.20 | ₹503.85 |
| 52 Week Range | ₹886.10 - ₹1,410.00 | ₹312.00 - ₹635.00 |
| % from 52W High | -20.77% | -20.65% |
| All-Time High | ₹1,410.00 (Jul 08, 2025) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -20.77% | -50.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.06% |
| Quarterly Earnings Growth | 0.05% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.21% | 0.08% |
| Operating Margin (TTM) | 0.23% | 0.10% |
| Return on Equity (TTM) | 0.19% | 0.12% |
| Debt to Equity (MRQ) | 2.27 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹389.23 | ₹149.84 |
| Cash per Share (MRQ) | ₹52.44 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹252.79M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹320.61M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.48% | 0.22% |
| Last 12-Month Dividend | ₹33.30 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Jenburkt vs Aarti Drugs
| Metric | JENBURPH | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.10 | 23.59 |
| Forward P/E | 33.54 | 14.97 |
| PEG Ratio | 33.54 | 0.37 |
| Price to Sales (TTM) | 3.34 | 1.83 |
| Price to Book (MRQ) | 3.00 | 3.25 |
| Market Capitalization | ||
| Market Capitalization | ₹5.16B | ₹44.42B |
| Enterprise Value | ₹4.97B | ₹50.34B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.21 | 2.08 |
| Enterprise to EBITDA | 12.64 | 17.02 |
| Risk & Other Metrics | ||
| Beta | 0.37 | 0.21 |
| Book Value per Share (MRQ) | ₹389.23 | ₹149.84 |
Financial Statements Comparison: Jenburkt vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | JENBURPH | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹410.47M | ₹6.77B |
| Cost of Goods Sold | ₹79.03M | ₹4.37B |
| Gross Profit | ₹331.44M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹100.67M | ₹784.50M |
| EBITDA | ₹127.38M | ₹951.90M |
| Pre-Tax Income | ₹118.35M | ₹711.50M |
| Income Tax | ₹32.99M | ₹83.80M |
| Net Income (Profit) | ₹85.37M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | JENBURPH | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹73.65M | ₹45.80M |
| Total Current Assets | ₹565.32M | ₹13.38B |
| Total Current Liabilities | ₹188.19M | ₹8.37B |
| Long-Term Debt | ₹14.92M | ₹2.86B |
| Total Shareholders Equity | ₹1.72B | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹144.29M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | JENBURPH | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | JENBURPH | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,161 | 159,509 |
| Average Daily Volume (90 Day) | 1,086 | 613,674 |
| Shares Outstanding | 4.41M | 91.27M |
| Float Shares | 1.77M | 35.46M |
| % Held by Insiders | 0.61% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Jenburkt vs Aarti Drugs
| Metric | JENBURPH | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹33.30 | ₹1.00 |
| Last 12-Month Dividend Yield | 2.48% | 0.22% |
| 3-Year Avg Annual Dividend | ₹19.90 | ₹1.00 |
| 3-Year Avg Dividend Yield | 1.83% | 0.23% |
| 3-Year Total Dividends | ₹59.70 | ₹3.00 |
| Ex-Dividend Date | Jul 11, 2025 | Feb 04, 2025 |